EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure

Kazuhiko Kido

Clinical Cardiology · 2026-07 · 49 (7)

DOI: 10.1002/clc.70405 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Cardiology, online erschienen am 07.07.2026. Verfasst von Kazuhiko Kido. Beteiligte Einrichtung: Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Maltose, Heart Failure, Ferric Compounds, Ferric Oxide, Saccharated. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited evidence comparing different intravenous (IV) iron products is available to guide the optimal IV iron product in patients with heart failure (HF) and iron deficiency (IDef).

Objectives

To compare ferric carboxymaltose (FCM) with iron sucrose in patients with HF with reduced or mildly reduced ejection fraction.

Methods

This single‐center retrospective cohort study included patients with HF with reduced or mildly reduced ejection fraction and IDef who received either FCM or iron sucrose. The primary outcome was IDef therapy goal achievement (defined as ferritin 100–300 mcg/L and iron saturation > 20%; ferritin > 300 mcg/L; or hemoglobin > 15 mg/dL regardless of iron study).

Results

A total of 78 patients in the FCM group and 21 in the iron sucrose group were included. The use of FCM was significantly associated with a higher rate of IDef treatment goal achievement after the induction course than iron sucrose (70.1 vs. 41.2%, p = 0.026). After adjusting for multiple variables, FCM use was significantly associated with a higher rate of the primary outcome than iron sucrose (adjusted OR 5.8 [95% CI 1.3‐26.1], p = 0.022). No significant difference in adherence to the IV iron criteria was found between the two groups (80.8 vs. 81.0%, p = 0.985).

Conclusion

Ferric carboxymaltose use was associated with a higher iron repletion rate than iron sucrose in patients with HF with reduced or mildly reduced ejection fraction and IDef.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MaltoseHeart FailureFerric CompoundsFerric Oxide, SaccharatedStroke VolumeVentricular Function, LeftAnemia, Iron-DeficiencyHumansRetrospective StudiesFemaleMaleTreatment OutcomeHematinicsAgedMiddle AgedBiomarkersFerritinsTime Factors

Stichwörter der Autor:innen

ferric carboxymaltoseheart failureintravenous ironiron deficiencyiron sucrose

Substanzen

ferric carboxymaltoseMaltoseFerric CompoundsFerric Oxide, SaccharatedHematinicsBiomarkersFerritins

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, USA.

Zitieren

APA

Kido, K. (2026). Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure. Clinical Cardiology, 49(7). https://doi.org/10.1002/clc.70405

Vancouver

Kido K. Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure. Clinical Cardiology. 2026;49(7). doi:10.1002/clc.70405

BibTeX
@article{Kido2026,
  author = {Kido, Kazuhiko},
  title = {Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure},
  journal = {Clinical Cardiology},
  year = {2026},
  volume = {49},
  number = {7},
  doi = {10.1002/clc.70405}
}
Kostenlos starten →